ALFA Filings
Every announcement, straight from the exchange
Every Alivus Life Sciences earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements with these filters
Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.
Alivus Life Sciences delivered strong Q1FY27 performance with revenue at ₹6,404 Mn and EBITDA margins expanding to 36.6%. The company is pivoting towards Non-GPL segments and CDMO growth.
Alivus (ex-Glenmark Life Sciences) reported strong Q4FY26 results with record 33.6% EBITDA margins, driven by non-GPL growth (71% of business) and CDMO recovery.
Alivus (formerly Glenmark Life Sciences) delivered record FY26 EBITDA margins of 33.6%, shifting successfully from GPL dependency to a more profitable non-GPL segment despite a major plant fire and global headwinds.
Alivus reported Q4FY26 revenue of ₹6,891 Mn (6.1% YoY) and PAT of ₹1,627 Mn (14.7% YoY). Strategy shifts from Glenmark-heavy mix to non-GPL (71% of revenue) under Nirma ownership.